Samuel Nee-Amugie Yartey

Samuel Nee-Amugie Yartey

Auto-generated profile, based on publicly available information

Samuel Nee-Amugie Yartey

Department of Medical Microbiology, University of Ghana Medical School, Korle Bu, Accra, Ghana

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
AAAnastasia Asantewaa
Anastasia Asantewaa
SYSamuel N.-A. Yartey
Samuel N.-A. Yartey
EDEric Donkor
Eric Donkor
This systematic review and meta-analysis aimed to quantify mortality associated with MRSA clones and evaluate the contribution of specific molecular features to outcome variation. Databases including PubMed, Scopus, Web of Science, and Google Scholar were searched for studies reporting mortality among patients with MRSA infection and associated molecular typing data, including clonal complex, sequence type and SCCmec type. Results were presented in thematic narratives, tables and figures. A random-effects meta-analysis was performed to estimate pooled mortality and prevalence proportions. Twenty-seven included studies reported on MRSA isolates from 12 different countries. The overall pooled mortality was 22.47% (95% CI: 17.31-28.07), with the highest mortality observed in Europe. Among MRSA clonal complexes, the highest mortality was observed among CC5 (50.75%), followed by CC8 (37.56%). Although ST72 (66.16%) was the most prevalent sequence type, the highest mortality rates were observed in ST764 (38.74%) and ST1 (38.72%). SCCmec type IV (36.95%) was dominant but had a lower mortality rate (18.71%) compared to types II (39.09%) and III (27.52%). The clear dominance and lethality of specific lineages affirm the clinical utility of molecular diagnostics in guiding treatment and predicting outcomes. These insights call for an expansion of MRSA typing programs in hospital laboratories and national surveillance systems.

14 November 2025 in Therapeutic Advances in Infectious Disease
Verified
Journal Article
Open access
SYSamuel Nee-Amugie Yartey
Samuel Nee-Amugie Yartey
AAAaron Awere-Duodu
Aaron Awere-Duodu
AAAnastasia Akosua Asantewaa
Anastasia Akosua Asantewaa
EDEric Donkor
Eric Donkor
Background: Antibiotic exposure disrupts microbial communities in the gut and respiratory tract, causing functional changes that may have lasting health impacts and contribute to the spread of antibiotic resistance genes (ARGs) throughout life. However, age-stratified evidence of these effects, particularly in low- and middle-income countries (LMICs), remains limited. Objective: This systematic review assessed the impact of antibiotics on gut and respiratory microbiomes and resistomes in LMICs, with separate analyses for adults and children. Data sources: PubMed, Scopus, Web of Science, & ScienceDirect. Methods: A comprehensive literature search was conducted using a predefined search strategy and eligibility criteria to identify relevant studies from LMICs. Twenty-five studies met the inclusion criteria: 23 examined the gut microbiome, and 2 focused on the respiratory microbiome. Key outcomes included microbial diversity (alpha/beta/gamma), taxonomic shifts, resistome profiles, functional changes, and recovery potentials, stratified by age group and body site. Results: Antibiotic exposure was generally associated with reductions in microbial diversity and altered taxonomic composition, with children showing more pronounced and prolonged disruptions than adults. Analysis of resistome changes revealed a critical finding: while antibiotics consistently selected for ARGs matching the drug class administered, a substantial reservoir of non-matching, background ARGs, conferring resistance to beta-lactams, aminoglycosides, vancomycin, tetracyclines, was also highly prevalent across studies. This indicates a silent pre-existing resistome that is enriched by antibiotic pressure. ARGs were more abundant in adult resistomes, though functional changes occurred across age groups. Microbiome recovery was observed over time, but resistome recovery was limited. Conclusion: Antibiotic use significantly disturbs the gut and respiratory microbiomes and promotes ARG enrichment, especially in children, who demonstrate greater susceptibility and lower recovery potential. These findings emphasise the need for targeted antibiotic stewardship, improved microbiome recovery research, and enhanced resistome monitoring in LMICs. Trail registration: International Prospective Register of Systematic Reviews (PROSPERO), ID: CRD420250641394.

27 March 2026 in Therapeutic Advances in Infectious Disease
Verified
Journal Article
Open access
EAEsther M. E. Asamoah
Esther M. E. Asamoah
AAAnastasia A. Asantewaa
Anastasia A. Asantewaa
SYSamuel N.-A. Yartey
Samuel N.-A. Yartey
NNNicholas Israel Nii-Trebi
Nicholas Israel Nii-Trebi
EDEric Donkor
Eric Donkor
Background: Hepatitis B virus (HBV) remains highly endemic in many low- and middle-income countries (LMICs), where challenges such as antiviral resistance and immune/vaccine-escape mutations complicate disease management. Objective: This review synthesizes current data on HBV drug resistance, including the prevalence and distribution of resistance-associated mutations (RAMs), vaccine-escape mutations (VEMs), and immune-escape mutations (IEMs) in LMICs. Design: Systematic review and meta-analysis. Data sources: PubMed, Scopus, and Web of Science. Methods: A systematic search was conducted from 2014 to 2025 (last search date: August 04, 2025), and data were extracted from eligible studies. A random-effects meta-analysis was conducted to estimate pooled resistance rates and prevalences. Results: A total of 43,834 participants from 47 studies conducted in 28 LMICs were included. The overall antiviral resistance rate was 7.87% (95% CI (5.13–11.11)), with very high heterogeneity ( I 2 = 99.7%). Lamivudine (3TC) and telbivudine (LdT) had the highest resistance rates. Asia consistently reported the greatest resistance, with rates of 32.45% for 3TC and 51.92% for LdT. In a subgroup analysis on economic regions, Lower-middle-income countries showed the highest pooled resistance rate at 10.61% (95% CI (5.21–17.51); I 2 = 96.9%). The most frequently detected RAMs were rtM204V/I, rtV173L, and rtL180M. The pooled prevalence of vaccine-escape mutations was 8.92% (95% CI (5.02–13.64); I 2 = 78.4%). Immune-escape mutations were much more common, with a pooled prevalence of 55.66% (95% CI (28.10–81.53); I 2 = 98.1%). The most prevalent mutations were sG145R/A/K, sQ129H/R, sD144E/A, sS143L/T, and sP120S/T. The pooled estimates in this study are reported and interpreted descriptively, given the substantial heterogeneity observed. Conclusion: The remarkably high drug resistance rates and prevalence of immune and vaccine-escape mutations suggest notable burdens of resistance, especially for drugs with low genetic barriers such as lamivudine and telbivudine, underscoring the growing challenges in achieving the WHO 2030 reduction goals, and highlighting the need for enhanced surveillance, adoption of potent antiviral regimens such as tenofovir disoproxil fumarate, and continuous vaccine efficacy monitoring. However, the results should be interpreted with caution due to the very high heterogeneity observed in the study. Trial registration: International prospective register of systematic reviews (PROSPERO) under the ID: CRD420251030302.